At the shareholder's annual meeting of Akeso Biopharma (Cayman) Limited held on June 30, 2024, all proposed resolutions were approved. The meeting was held in Zhongshan City, Guangdong Province, China and was chaired by Executive Director Dr. Xia Yu. Shareholders approved multiple resolutions, including the audited comprehensive financial statements of the company and its subsidiaries for the fiscal year ended December 31, 2023, as well as the board of directors' and auditors' reports. In addition, shareholders also agreed to re-elect Executive Directors Dr. Xia Yu, Dr. Li Baiyong, and Dr. Wang Zhongmin, and authorized the board of directors to set director remuneration. Ernst & Young was reappointed as the company's auditor, and the board of directors was authorized to set their remuneration...Show More

At the shareholder's annual meeting of Akeso Biopharma (Cayman) Limited held on June 30, 2024, all proposed resolutions were approved. The meeting was held in Zhongshan City, Guangdong Province, China and was chaired by Executive Director Dr. Xia Yu. Shareholders approved multiple resolutions, including the audited comprehensive financial statements of the company and its subsidiaries for the fiscal year ended December 31, 2023, as well as the board of directors' and auditors' reports. In addition, shareholders also agreed to re-elect Executive Directors Dr. Xia Yu, Dr. Li Baiyong, and Dr. Wang Zhongmin, and authorized the board of directors to set director remuneration. Ernst & Young was reappointed as the company's auditor, and the board of directors was authorized to set their remuneration. Shareholders also approved the general authorization for the issuance and repurchase of company shares, as well as the amendment proposals for the 2021 Restricted Stock Unit Plan and Stock Option Plan. The voting results of the shareholder's annual meeting showed that all resolutions received more than 50% of the affirmative votes, and the total number of valid votes cast was 837,912,097 shares, accounting for approximately 96.77% of the total issued shares.